Correlation between glycemic control, lipid profile and C-reactive protein in adults with type 2 diabetes mellitus done in a tertiary care hospital of Nellore, Andhra Pradesh, India

Rajesh Kumar Meriga, Vishnu Anjan Nareddy, Sriram Venkata Sudha Sai Bhavya, Challa Sreekeerthi


Background: Diabetes mellitus refers to a group of common metabolic disorders that shares the phenotype of hyperglycemia. Complications of diabetes mellitus involve many organ systems only to play an important role in morbidity and mortality. Poor glycemic control is significantly associated with the development of macrovascular complications. Earlier studies have indicated that C-reactive protein (CRP) is an important risk factor for cardiovascular disease as evident from its higher levels in people with diabetes mellitus compared to those without. Not much is known whether CRP is related to the level of glycemic control. The purpose of this study is, to determine the relation between HbA1C, Lipid profile and CRP in individuals with type 2 diabetes mellitus.

Methods: Fifty patients with T2DM reporting to Narayana Medical College and Hospital were included in the study, in whom CRP levels were estimated by using commercially available kits and correlated with HbA1C and other risk factors of coronary artery disease. Follow-up was done on 20 patients who were not on statin therapy with repeat HbA1C and CRP.

Results: This study showed that both HbA1C and CRP levels had reduced significantly in follow-up patients after putting them on treatment (p<0.05). It was also found that lower the HbA1C, lower was the CRP. A positive correlation was found between HbA1C and CRP (p<0.05).

Conclusions: In this study of 50 patients with T2DM, it was found that CRP is significantly correlated with HbA1C level. A positive correlation was found between serum CRP and HbA1C in the initial group and in the follow-up patients, showing that CRP levels lowers with better glycemic control and correlates with dyslipidaemia profile.


C-reactive protein, Glycemic control, Hemoglobin A1C, Type 2 diabetes mellitus

Full Text:



WHO consultation group. Definition, diagnosis, and classification of diabetes mellitus and its complications, 2nd Ed. Part 1: diagnosis and classification of diabetes mellitus WHO/NCD/NCS/99. Geneva: World Health Organisation. 1999;1-59.

International diabetes federation. IDF Diabetes Atlas Eighth edition 2017, Brussels, Belgium, 2017. Available at: at /2017.html/. Accessed on 12th May 2020.

Gu K, Cowie CC, Harris MI. Mortality in adults with and without diabetes in a national cohort of the U.S. population, 1971-1993. Diabetes Care. 1998;21:1138-45.

Ford ES. The metabolic syndrome and C-reactive protein, fibrinogen, and leukocyte count: findings from the third National health and nutrition examination survey. Atheroscl. 2003;168:351-8.

Pickup J, Crook M. Is type II diabetes mellitus a disease of the innate immune system? Diabetol. 1998;41:1241-8.

Pickup JC, Mattock MB, Chusney GD, Burt D. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetol. 1997;40(11):1286.

Bax JJ, van der Wall EE. Assessment of coronary artery disease in patients with (a) symptomatic diabetes. European Heart J. 2006;27:631-2.

Pradhan AD, Manson JE, Rifai N, Buring JE, Ridker PM. C-reactive protein, interleukin 6, and risk of developing type 2 diabetes mellitus. JAMA. 2001;286(3):327-34.

Expert panel on blood rheology. Guidelines on selection of laboratory tests for monitoring the acutephase response. J Clin Pathol. 1988;41:1203-12.

Yudkin JS, Stehouwer C, Emeis J, Coppack S. C-reactive protein in healthy subjects: associations with obesity, insulin resistance, and endothelial dysfunction: a potential role for cytokines originating from adipose tissue?. Arterioscler Thromb Vasc Biol. 1999;19:972-8.

Howard D, Buring J, Rifai N, Blake G, Michael G, Ridker P. C-reactive protein and the risk of developing hypertension. JAMA. 2003;290:2945-51.

Ridker PM. Rosuvastatin in the primary prevention of cardiovascular disease among patients with low levels of low-density lipoprotein cholesterol and elevated high-sensitivity C-reactive protein: Rationale and design of the JUPITER trial. Circulat. 2003;11:108(19):2292-7.

Ridker PM, Buring JE, Cook NR, Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14 719 initially healthy American women. Circulat. 2003;107(3):391-7.

Balk EM, Lau J, Goudas LC, Jordan HS, Kupelnick B, Kim LU, et al. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann Intern Med. 2003;139:670-82.

King DE, Mainous AG, Buchanan TA, Pearson WS. C-reactive protein and glycemic control in adults with diabetes. Diabetes Care. 2003;26:1535-9.

Hu G, Jousilahti P, Tuomilehto J, Antikainen R, Sundvall J, Salomaa V. Association of serum C-reactive protein level with sex-specific type 2 diabetes risk: a prospective finnish study. J Clin Endocrinol Metabol. 2009;94(6):2099-105.

Williams MJ, Williams SM, Milne BJ, Hancox RJ, Poulton R. Association between C-reactive protein, metabolic cardiovascular risk factors, obesity and oral contraceptive use in young adults. Inter J Obes. 2004;28:998-1003.

Michelle A, Robert J, Paul MP. Plasma concentration of c-reactive protein and the calculated framingham coronary heart disease risk score. Circulat. 2003;108:161-5.

Steven E, Murat T, Paul S, Tim C, Sasiela WJ, John T, et al. C-reactive protein, and coronary artery disease. N Engl J Med. 2005;352:29-38.

Takiko Y, Atura T, Mitsuo F, Yoshikatsu N, Shoichiro N, Minako O, et al. Leptin, triglycerides, and interleukin 6 are independently associated with C-reactive protein in Japanese type 2 diabetic patients. Diab Res Clin Pract. 2007;75:2-6.

Ana ML, Eridan S, Carol LF, Agnaluce M, Angela H, Luis A. Association between elevated serum c-reactive protein and triglyceride levels in young subjects with type 1 diabetes. Diabetes Care. 2006;29:424-6.